IQVIA Holdings Inc. (NYSE:IQV) Shares Acquired by Capital Research Global Investors

Capital Research Global Investors lifted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 0.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,535,854 shares of the medical research company's stock after purchasing an additional 3,193 shares during the quarter. Capital Research Global Investors owned about 0.85% of IQVIA worth $301,817,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in IQV. Synergy Asset Management LLC acquired a new stake in shares of IQVIA during the 4th quarter valued at approximately $33,000. GKV Capital Management Co. Inc. acquired a new position in IQVIA during the fourth quarter worth $39,000. Lee Danner & Bass Inc. purchased a new stake in IQVIA during the fourth quarter worth $44,000. Zions Bancorporation N.A. increased its position in shares of IQVIA by 55.2% in the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after buying an additional 85 shares in the last quarter. Finally, Versant Capital Management Inc boosted its position in shares of IQVIA by 46.0% in the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock worth $58,000 after buying an additional 93 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on IQV shares. UBS Group lowered their target price on IQVIA from $260.00 to $255.00 and set a "buy" rating on the stock in a report on Friday, February 7th. Robert W. Baird reduced their target price on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a report on Tuesday, January 21st. Stifel Nicolaus decreased their target price on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a research report on Friday, February 7th. Citigroup cut their price target on IQVIA from $225.00 to $210.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Finally, Barclays restated an "equal weight" rating and set a $170.00 price objective (down previously from $235.00) on shares of IQVIA in a report on Thursday, April 10th. Six investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, IQVIA currently has an average rating of "Moderate Buy" and a consensus target price of $241.50.

IQVIA Stock Up 2.5 %

NYSE:IQV traded up $3.64 during mid-day trading on Thursday, reaching $150.70. The stock had a trading volume of 1,457,527 shares, compared to its average volume of 1,419,786. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The company has a market capitalization of $26.57 billion, a price-to-earnings ratio of 20.09, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46. IQVIA Holdings Inc. has a 1-year low of $135.97 and a 1-year high of $252.88. The stock's 50 day simple moving average is $173.32 and its two-hundred day simple moving average is $195.09.

IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.